Is genetic testing of healthy pre-symptomatic children with possible Alport syndrome ethical?

Pediatric Nephrology

Volumn 21, Issue 4, 2006, Pages 455-456

  Copelovitch, Lawrence ^a   Kaplan, Bernard S ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPORT SYNDROME; CHILD; EARLY DIAGNOSIS; EDITORIAL; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOTE; HUMAN; KIDNEY POLYCYSTIC DISEASE; LABORATORY TEST; MEDICAL ETHICS; MENTAL DISEASE; MUTATIONAL ANALYSIS; ONSET AGE; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SOCIAL DISCRIMINATION; SYMPTOM;

CHILD; GENETIC SCREENING; HUMANS; NEPHRITIS, HEREDITARY;

EID: 33645370508     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-005-0003-4     Document Type: Editorial

References (13)

1. Slajpah M, Meglic A, Furlan P, Glavac D (2005) The importance of non-invasive genetic analysis in the initial diagnosis of Alport syndrome in young patients. Pediatr Nephrol 20:1260-1264
2. Nelson RM, Botkjin JR, Kodish ED, Levetown M, Truman JT, Wilfond BS, Harrison CE, Kazura A, Krug E 3rd, Schwartz PA, Donovan GK, Fallat M, Porter IH, Steinberg D (2001) Committee on bioethics. Ethical issues with genetic testing in pediatrics. Pediatrics 107:1451-1455
3. Ravine DL, Walker RG, Gibson RN, Forrest SM, Richards RI, Friend K, Sheffield LJ, Kincaid-Smith P, Danks DM (1992) Phenotype and genotype heterogeneity in autosomal dominant polycystic kidney disease. Lancet 340:1330-1333
4. Marsick R, Limwongse C, Kodish E (1998) Genetic testing for renal diseases: Medical and ethical considerations. Am J Kidney Dis 32:943-945
5. Anonymous (1995) Points to consider: Ethical, legal, and psychosocial implications of genetic testing in children and adolescents. American Society of Human Genetics Board of Directors; American College of Medical Genetics Board of Directors. Am J Hum Genet 57:1233-1241
6. Chapman MA (1992) Canadian experience with predictive testing of Huntington disease: Lessons for genetic testing centers and policy makers. Am J Med Genetics 42:491-498
7. Wexler N (1992) The Tiresias complex: Huntington's disease as a paradigm of testing for late-onset disorders. FASEB J 6:2820-2825
8. Jais JP, Kenebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, Weber M, Gross O, Nezter KO, Flinter F, Pirson Y, Verellen C, Wieslander J, Persson U, Tryggvason K, Martin P, Hertz JM, Schroder C, Sanak M, Krejcova S, Carvalho MF, Saus J, Antignac C, Smeets H, Gubler MC (2000) X-linked Alport syndrome: Natural history in 195 families and genotype-phenotype correlations in males. J Am Soc Nephrol 11:649-657
9. Gross O, Netzer KO, Lambrect R, Seibold S, Weber M (2002) Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: Impact on clinical counseling. Nephrol Dial Transplant 17:1218-1227
10. Feld LG, Meyers KE, Kaplan BS, Stapleton FB (1998) Limited evaluation of microscopic hematuria in pediatrics. Pediatrics 102:E42
11. Bergstein J, Leiser J, Andreoli S (2005) The clinical significance of asymptomatic gross and microscopic hematuria in children. Arch Pediatr Adolesc Med 159:353-355
12. Diven SC, Travis LB (2000) A practical primary care approach to hematuria in children. Pediatr Nephrol 14:65-72
13. Rana K, Wang YY, Powell H, Jones C, McCreie D, Buzza M, Udawela M, Savige J (2005) Persistent familial hematuria in children and the locusfor thin basement membrane nephropathy. Pediatr Nephrol 20:1729-1737